Ryan Cohlhepp Sells 3,828 Shares of Bicara Therapeutics (NASDAQ:BCAX) Stock

Bicara Therapeutics Inc. (NASDAQ:BCAX) COO Ryan Cohlhepp sold 3,828 shares of the firm’s stock in a transaction on Thursday, January 22nd. The shares were sold at an average price of $18.10, for a total value of $69,286.80. Following the sale, the chief operating officer directly owned 210,164 shares of the company’s stock, valued at $3,803,968.40. This represents a 1.79% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink.

Ryan Cohlhepp also recently made the following trade(s):

• On Thursday, January 15th, Ryan Cohlhepp sold 149 shares of Bicara Therapeutics stock. The stock was sold at an average price of $18.02, for a total value of $2,684.98.
• On Monday, December 15th, Ryan Cohlhepp sold 12,500 shares of Bicara Therapeutics stock. The shares were sold at an average price of $18.68, for a total value of $233,500.00.
• On Friday, November 21st, Ryan Cohlhepp sold 12,500 shares of Bicara Therapeutics stock. The stock was sold at an average price of $18.05, for a total transaction of $225,625.00.

Bicara Therapeutics Trading Up 2.1%

BCAX opened at $16.77 on Wednesday. Bicara Therapeutics Inc. has a 1-year low of $7.80 and a 1-year high of $19.71. The stock has a market capitalization of $918.69 million, a PE ratio of -7.49 and a beta of -0.79. The firm has a 50-day moving average price of $17.50 and a two-hundred day moving average price of $14.82.

Bicara Therapeutics (NASDAQ:BCAX) last issued its quarterly earnings results on Monday, November 10th. The company reported ($0.67) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.55) by ($0.12). On average, research analysts predict that Bicara Therapeutics Inc. will post -2.59 EPS for the current year.

Analyst Upgrades and Downgrades

A number of analysts recently commented on the company. HC Wainwright reiterated a “buy” rating on shares of Bicara Therapeutics in a research report on Wednesday, January 14th. Weiss Ratings reissued a “sell (d-)” rating on shares of Bicara Therapeutics in a research note on Friday, January 9th. Mizuho raised shares of Bicara Therapeutics to a “hold” rating in a research note on Thursday, December 18th. UBS Group reiterated a “buy” rating on shares of Bicara Therapeutics in a research report on Wednesday, January 14th. Finally, BTIG Research restated a “buy” rating on shares of Bicara Therapeutics in a research report on Thursday, January 15th. Six investment analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $28.00.

Institutional Trading of Bicara Therapeutics

A number of large investors have recently made changes to their positions in BCAX. Vestal Point Capital LP lifted its holdings in Bicara Therapeutics by 2.0% during the third quarter. Vestal Point Capital LP now owns 5,100,000 shares of the company’s stock worth $80,529,000 after acquiring an additional 100,000 shares in the last quarter. Vanguard Group Inc. raised its position in shares of Bicara Therapeutics by 9.8% during the third quarter. Vanguard Group Inc. now owns 2,200,925 shares of the company’s stock worth $34,753,000 after purchasing an additional 195,667 shares during the period. Millennium Management LLC lifted its holdings in shares of Bicara Therapeutics by 37.0% during the 3rd quarter. Millennium Management LLC now owns 1,014,892 shares of the company’s stock valued at $16,025,000 after purchasing an additional 273,873 shares in the last quarter. Geode Capital Management LLC grew its position in shares of Bicara Therapeutics by 36.8% in the 2nd quarter. Geode Capital Management LLC now owns 672,485 shares of the company’s stock valued at $6,248,000 after purchasing an additional 180,833 shares during the period. Finally, Schonfeld Strategic Advisors LLC increased its stake in Bicara Therapeutics by 91.8% during the 3rd quarter. Schonfeld Strategic Advisors LLC now owns 504,085 shares of the company’s stock worth $7,959,000 after purchasing an additional 241,334 shares in the last quarter.

Bicara Therapeutics Company Profile

Bicara Therapeutics is a clinical-stage biopharmaceutical company dedicated to developing novel neurohormone-based therapies for psychiatric and neurological disorders. The company’s research focuses on harnessing endogenous signaling pathways in the brain, with the goal of offering new treatment options for conditions that remain inadequately addressed by existing medications. Bicara applies proprietary peptide engineering and intranasal delivery platforms to optimize central nervous system uptake and therapeutic effect.

The company’s lead candidates include PST-001, an intranasal vasopressin-1A receptor antagonist in development for postpartum depression, and PST-002, an oxytocin receptor modulator being investigated for social anxiety and autism spectrum disorder.